Markus Sieger - 02 Aug 2022 Form 4 Insider Report for Cyclo Therapeutics, Inc. (CYTH)

Reporting relationship: Director
Issuer ticker: CYTH
Reported as of: 02 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2022, 16:03:26 UTC
Prior SEC filing: 04 May 2022
Next SEC filing: 09 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Markus Sieger

Key filing fact

Markus Sieger filed Form 4 for Cyclo Therapeutics, Inc. (CYTH) on 04 Aug 2022.

Key facts

This page summarizes Markus Sieger's Form 4 filing for Cyclo Therapeutics, Inc. (CYTH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Aug 2022, 16:03.

Change

Previous filing in this sequence was filed on 04 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYTH transaction

Common Stock

Award

Transaction value: $0
Shares: +5,762
Change %: +6.7%
Price: $0.000000
Shares after: 91,674
Date: 02 Aug 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the second quarter of 2022. The number of shares received in lieu of cash was calculated based on the closing price of 1.92 per share of common stock on August 1, 2022.